Bridging Gaps in Evidence-based Clinical Practice in Inflammatory Bowel Diseases: Observational Comparative Effectiveness Research for the Win.
作者信息
Scott Frank I, Singh Siddharth
机构信息
Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Division of Gastroenterology and Division of Biomedical Informatics, University of California San Diego, La Jolla, California.
出版信息
Clin Gastroenterol Hepatol. 2019 Aug;17(9):1726-1728. doi: 10.1016/j.cgh.2018.12.047. Epub 2019 Jan 7.
Abstract
摘要
相似文献
1
Bridging Gaps in Evidence-based Clinical Practice in Inflammatory Bowel Diseases: Observational Comparative Effectiveness Research for the Win.弥合炎症性肠病循证临床实践中的差距：观察性比较效果研究大获成功。
Clin Gastroenterol Hepatol. 2019 Aug;17(9):1726-1728. doi: 10.1016/j.cgh.2018.12.047. Epub 2019 Jan 7.
2
What is the need for comparative effectiveness studies in IBD?炎症性肠病中进行比较疗效研究的必要性是什么？
Expert Rev Gastroenterol Hepatol. 2014 Nov;8(8):851-4. doi: 10.1586/17474124.2014.945916. Epub 2014 Aug 6.
3
Comparative effectiveness research in inflammatory bowel disease: prospects and challenges.
Expert Rev Gastroenterol Hepatol. 2012 Aug;6(4):405-7. doi: 10.1586/egh.12.28.
4
Comparative effectiveness research in inflammatory bowel disease.
Inflamm Bowel Dis. 2011 Jun;17(6):E46-7. doi: 10.1002/ibd.21693. Epub 2011 Mar 18.
5
Safety of anti-TNF biologics in paediatric inflammatory bowel disease.抗TNF生物制剂在儿童炎症性肠病中的安全性。
Lancet Gastroenterol Hepatol. 2019 Nov;4(11):813-815. doi: 10.1016/S2468-1253(19)30292-4. Epub 2019 Sep 4.
6
Effectiveness Research in Inflammatory Bowel Disease: A Necessity and a Methodological Challenge.炎症性肠病的有效性研究：必要性与方法学挑战
J Crohns Colitis. 2016 Sep;10(9):1096-102. doi: 10.1093/ecco-jcc/jjw068. Epub 2016 Mar 3.
7
Comparative effectiveness research in obstructive sleep apnea: bridging gaps between efficacy studies and clinical practice.阻塞性睡眠呼吸暂停的疗效比较研究：弥合疗效研究与临床实践之间的差距。
J Comp Eff Res. 2012 Jan;1(1):83-105. doi: 10.2217/cer.11.12.
8
Editorial: paradoxical skin lesions during anti-TNF treatment-an additional argument to consider new biologics as first line therapy in inflammatory bowel disease.社论：抗TNF治疗期间出现的矛盾性皮肤病变——将新型生物制剂作为炎症性肠病一线治疗方案考虑的又一论据
Aliment Pharmacol Ther. 2018 Sep;48(6):683-684. doi: 10.1111/apt.14903.
9
A Systematic Review of the Cost-Effectiveness of Biologics for the Treatment of Inflammatory Bowel Diseases.生物制剂治疗炎症性肠病的成本效益系统评价
PLoS One. 2015 Dec 16;10(12):e0145087. doi: 10.1371/journal.pone.0145087. eCollection 2015.
10
Editorial: paradoxical skin lesions during anti-TNF treatment-an additional argument to consider new biologics as first-line therapy in inflammatory bowel disease. Authors' reply.社论：抗TNF治疗期间出现的矛盾性皮肤病变——将新型生物制剂作为炎症性肠病一线治疗方案考虑的又一论据。作者回复
Aliment Pharmacol Ther. 2018 Sep;48(6):684-685. doi: 10.1111/apt.14917.
引用本文的文献
1
Surgeons Knowledge, Attitude, and Practice Toward Preoperative Inflammatory Bowel Disease Medications and Post-Operative Complications.外科医生对术前炎症性肠病药物及术后并发症的知识、态度和实践
Ther Clin Risk Manag. 2025 Jul 22;21:1149-1159. doi: 10.2147/TCRM.S527037. eCollection 2025.
本文引用的文献
1
Concomitant Use of Aminosalicylates Is Not Associated With Improved Outcomes in Patients With Ulcerative Colitis Escalated to Vedolizumab.氨基水杨酸盐的联合使用与溃疡性结肠炎患者升级为维得利珠单抗后改善结局无关。
Clin Gastroenterol Hepatol. 2019 Oct;17(11):2374-2376.e2. doi: 10.1016/j.cgh.2018.11.062. Epub 2018 Dec 7.
2
Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.在一项基于人群的队列研究中，与单药治疗相比，未接受过生物制剂治疗的患者采用 upfront 联合治疗与炎症性肠病相关并发症风险降低相关。
Clin Gastroenterol Hepatol. 2019 Aug;17(9):1788-1798.e2. doi: 10.1016/j.cgh.2018.11.003. Epub 2018 Nov 15.
3
Early Initiation of Tumor Necrosis Factor Antagonist-Based Therapy for Patients With Crohn's Disease Reduces Costs Compared With Late Initiation.与晚期开始使用肿瘤坏死因子拮抗剂治疗相比，早期开始使用肿瘤坏死因子拮抗剂治疗克罗恩病可降低成本。
Clin Gastroenterol Hepatol. 2019 Jul;17(8):1515-1524.e4. doi: 10.1016/j.cgh.2018.07.032. Epub 2018 Jul 26.
4
Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases.炎症性肠病治疗相关的严重和机会性感染风险。
Gastroenterology. 2018 Aug;155(2):337-346.e10. doi: 10.1053/j.gastro.2018.04.012. Epub 2018 Apr 12.
5
Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease.与抗肿瘤坏死因子-α靶向治疗相比，延长皮质类固醇治疗与炎症性肠病的死亡率增加有关。
Am J Gastroenterol. 2018 Mar;113(3):405-417. doi: 10.1038/ajg.2017.479. Epub 2018 Jan 16.
6
Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease.硫嘌呤类药物或肿瘤坏死因子拮抗剂单独使用或联合使用与炎症性肠病患者淋巴瘤风险之间的关联
JAMA. 2017 Nov 7;318(17):1679-1686. doi: 10.1001/jama.2017.16071.
7
Comparison of Infliximab and Adalimumab in Biologic-Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study.英夫利昔单抗与阿达木单抗治疗初治溃疡性结肠炎患者的比较：丹麦全国队列研究
Clin Gastroenterol Hepatol. 2017 Aug;15(8):1218-1225.e7. doi: 10.1016/j.cgh.2016.11.024. Epub 2016 Nov 29.
8
Genome privacy: challenges, technical approaches to mitigate risk, and ethical considerations in the United States.基因组隐私：美国面临的挑战、降低风险的技术方法及伦理考量
Ann N Y Acad Sci. 2017 Jan;1387(1):73-83. doi: 10.1111/nyas.13259. Epub 2016 Sep 28.
9
Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial.阿达木单抗单药治疗及与硫唑嘌呤联合治疗克罗恩病：一项前瞻性随机试验
J Crohns Colitis. 2016 Nov;10(11):1259-1266. doi: 10.1093/ecco-jcc/jjw152. Epub 2016 Aug 26.
10
Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer.自身免疫性疾病和非黑色素瘤皮肤癌病史患者使用免疫抑制剂和生物制剂与非黑色素瘤皮肤癌的风险
JAMA Dermatol. 2016 Feb;152(2):164-72. doi: 10.1001/jamadermatol.2015.3029.
Zotero 插件